Floatz logo

hrs9531

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Fujian Shengdi Pharmaceutical Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

130 Active assets in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

hrs9531 is also rated in:

obesity disorderDormant
BB
Indicative ·
68 / 100
View asset →
diastolic heart failureDormant
CCC
Indicative ·
53 / 100
View asset →
Overweight or Obesity; Type 2 DiabetesDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →